RxDoctor Payments Data

Lissette Cortes-Meyer, APRN

Adult Health · Winter Haven, FLNPI 1598035610

Payments from drug & device makers

$4,825in general payments, 2019–2025

Across 181 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Merck$586
  • AstraZeneca$494
  • Boehringer Ingelheim$366
  • Amgen$348
  • Amarin Pharma, Inc.$268
  • plus $972 from 11 others

What the payments were for

  • Travel & lodging$93519%
  • Food & beverage$3,87280%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,825 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$11,626
Medicare patients
75
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$289,430
EntrestoSacubitril/Valsartan149$164,200
JardianceEmpagliflozin59$66,456
XareltoRivaroxaban48$45,535
Repatha SureclickEvolocumab59$44,836
FarxigaDapagliflozin Propanediol21$28,646
Metoprolol Succinate372$6,009
Ranolazine ErRanolazine40$2,585
Amiodarone Hcl77$2,418
Atorvastatin Calcium138$1,637
Rosuvastatin Calcium105$1,564
Losartan Potassium146$1,462
Ezetimibe77$1,384
Hydralazine Hcl78$1,313
Amlodipine Besylate196$1,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$289,430327 claims
Boehringer IngelheimJardiance$366$66,45659 claims
Johnson & JohnsonXarelto$69$45,53548 claims
AstraZenecaFarxiga$494$28,64621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.

Other adult health in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →